Clinical trials: Buprenorphine
Drug Addiction
Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)
This study was a survey of drug users who obtain buprenorphine from the black market and have used buprenorphine during the last month.
- Trial name
- NCT00756353
- Volunteers
- 600 people
- Sponsor
- Indivior Inc.
Opioid Withdrawal, Pain
BRIDGE Device for Treatment of Opioid Withdrawal
The purpose of this study is to prospectively evaluate the effectiveness of the NSS-2 BRIDGE device in reducing the signs and symptoms of acute opioid withdrawal when compared to placebo.
- Conditions
- Opioid Withdrawal, Pain, Craving
- Trial name
- NCT04162145
- Testing
- Active BRIDGE device placement, Inactive BRIDGE device placement
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BrightView LLC
Pain
Compare the Efficacy and Safety of Norspan to Tramadol/Acetaminophen With Prolonged Postoperative Pain (PASSION)
The purpose of this study is to compare the efficacy and safety of buprenorphine transdermal system to tramadol/acetaminophen.
- Trial name
- NCT01983111
- Testing
- buprenorphine, tramadol/acetaminophen
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Mundipharma Korea Ltd
Post-operative Pain
Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
This is a phase 3, multicenter, randomized, double-blind, multiple-dose, parallel-group, placebo-controlled study to evaluate the safety and efficacy of up to 3 dosing regimens of Buprenorphine Sublingual (under the tongue) Spray…
- Trial name
- NCT02310581
- Testing
- Buprenorphine Sublingual Spray
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Substance Withdrawal Syndrome, Opiate Addiction
Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction
The purpose of this study is to evaluate the relative exposures of lofexidine and its major metabolites in subjects seeking buprenorphine dose reduction.
- Conditions
- Substance Withdrawal Syndrome, Opiate Addiction, Opiate Dependence
- Trial name
- NCT02801357
- Testing
- lofexidine administration in subjects seeking buprenorphine dose reduction
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Chronic Pain, Osteoarthritis of the Knee
Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee
The objective of this study is to determine the analgesic efficacy and safety of Buprenorphine Transdermal System (BTDS) 10 and 20 compared to placebo in opioid-naïve subjects with moderate to severe chronic pain due to…
- Trial name
- NCT00531427
- Testing
- Buprenorphine
- Where
- 87 sites in United States
- Volunteers
- 567 people
- Sponsor
- Purdue Pharma LP
Opioid-use Disorder
CBT4CBT for Office Based Buprenorphine
In this Phase II SBIR/STTR project, our Specific Aim will be to determine if the use of CBT4CBT-Buprenorphine leads to clinically significant improved outcomes and increased retention for buprenorphine maintenance patients in a…
- Trial name
- NCT03580902
- Testing
- CBT4CBT-Buprenorphine, Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- CBT4CBT, LLC
ECG Effects
The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers
The purpose of this study is to evaluate the ECG effects of 10, 40, and 80 mcg/hr buprenorphine delivered by BTDS alone, or by BTDS dosed with naltrexone, relative to placebo in healthy male and female subjects.
- Trial name
- NCT01999114
- Testing
- Buprenorphine transdermal patch, Naltrexone tablet, Moxifloxacin tablet
- Where
- United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Opioid Withdrawal
Open-Label, Safety Study of Lofexidine
The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and…
- Trial name
- NU LEAF (NCT02363998)
- Testing
- Lofexidine
- Where
- 18 sites in United States
- Volunteers
- 286 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Opioid Use Disorders
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and…
- Trial name
- NCT02651584
- Testing
- CAM2038 SC injection, SL BPN/NX tabs
- Where
- 36 sites in United States
- Volunteers
- 428 people
- Sponsor
- Braeburn Pharmaceuticals
Osteoarthritis Pain of the Hip and or Knee
Norspan Efficacy and Safety Among Elderly Subjects
An open label, multi-centre, prospective age-group-controlled study to evaluate efficacy and safety of buprenorphine transdermal patches in subjects with chronic, moderate to severe osteoarthritis pain of the hip and/or knee.
- Trial name
- NCT01276431
- Testing
- Buprenorphine transdermal patch
- Where
- 2 sites in Sweden
- Volunteers
- 102 people
- Sponsor
- Mundipharma AB
Buprenorphine, Naloxone
Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)
The purpose of this study is to assess the risks of abuse, misuse and adverse events related to high dose buprenorphine. Approximately 1250 patients taking Subutex (Schering-Plough) or its Buprenorphine High Dose (BHD) generic…
- Conditions
- Buprenorphine, Naloxone, Opiate-related Disorders, Opiate Dependence
- Trial name
- OPUS R (NCT00723697)
- Testing
- buprenorphine
- Volunteers
- 1,307 people
- Sponsor
- Indivior Inc.
Opioid Use Disorder
Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations
Extended-release buprenorphine (SUBLOCADE®) injection is currently approved for subcutaneous administration in the abdomen for treatment of opioid use disorder (OUD).
- Trial name
- NCT05704543
- Testing
- Buprenorphine Extended-Release Injection
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- Indivior Inc.
Opioid Use Disorder
Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT
The goal of this clinical trial is to examine the usefulness of a virtual reality-delivered intervention for individuals with opioid use disorder who are taking medication.
- Trial name
- NCT06021431
- Testing
- MORE-VR, Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 128 people
- Sponsor
- BehaVR LLC
Inguinal Hernia, Pain, Postoperative
Transversus Abdominis Plane Block With or Without Buprenorphine After Inguinal Hernia Surgery
Buprenorphine intravenous, sublingual, and transdermal patches have been researched for their antihyperalgesic effects, although peripherally mediated effects have not been examined in Egypt surprisingly
- Trial name
- NCT05549492
- Testing
- Ropivacaine 0.25%-NaCl 0.9% Injectable Solution
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Egymedicalpedia
Renal Impairment
Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function
This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.
- Trial name
- NCT02508506
- Testing
- ALKS 5461
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Pain, Osteoarthritis
Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain
The primary objective of this study is to evaluate the efficacy and safety of BTDS compared to placebo in subjects with moderate to severe osteoarthritic pain of the hip or knee.
- Trial name
- NCT00345787
- Testing
- Buprenorphine Transdermal System
- Where
- 28 sites in Japan
- Volunteers
- 262 people
- Sponsor
- Mundipharma K.K.
Pain, Low Back Pain
Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain
The purpose of this study is to determine whether BEMA Buprenorphine is safe in the treatment of chronic pain.
- Conditions
- Pain, Low Back Pain, Osteoarthritis, Neuropathic Pain
- Trial name
- NCT01298765
- Testing
- BEMA Buprenorphine
- Where
- 26 sites in United States
- Volunteers
- 302 people
- Sponsor
- BioDelivery Sciences International
Opioid Dependence
Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
The primary objective of this study is to compare overall patient preference for either Suboxone® sublingual film 8/2 or Zubsolv® sublingual tablets 5.7/1.4.
- Trial name
- NCT02038790
- Testing
- Suboxone Sublingual Film, Zubsolv sublingual tablets
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Indivior Inc.
Other Acute Postoperative Pain, Prolonged Endotracheal Intubation
Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain
The purpose of this study is to characterize the safety, pharmacokinetics (PK), and efficacy of intravenous (IV) buprenorphine in pediatric patients.
- Trial name
- NCT01324544
- Testing
- Buprenorphine IV
- Sponsor
- Purdue Pharma LP